

In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claims 4-7 without prejudice or disclaimer.

Please amend pending claims 1, 3, 9, and 50 as noted below.

1. (Currently Amended). An isolated nucleic acid molecule selected from the group consisting of:

(a) a nucleic acid molecule ~~which hybridizes at 65°C in hybridization buffer consisting essentially of 3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH₂PO₄(pH7), 0.5% SDS, 2mM EDTA, to a molecule~~ consisting of the nucleic acid of SEQ ID NO:1 or SEQ ID NO:3 ~~and which codes for a polypeptide that binds the Epidermal Growth Factor Receptor and downregulates its expression,~~

(b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code, and

(c) complements of (a) or (b).

2. (Original) The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:1.

3. (Currently Amended). The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule is the nucleic acid molecule of SEQ ID NO:3 ~~or a fragment thereof.~~

4-7. (Canceled).

9. (Currently Amended). An expression vector comprising the isolated nucleic acid molecule of claim [[4]] 1 operably linked to a promoter.

31 AVAILABLE COPY

11. (Original) A host cell transformed or transfected with the expression vector of claim 9.

50. (Currently Amended) A pharmaceutical composition comprising:
~~a pharmaceutically effective amount of an agent comprising~~ of an isolated nucleic acid molecule of claim 1 or an expression product thereof, and a pharmaceutically acceptable carrier.

BEST AVAILABLE COPY